Methods for using glucose pentasulfate for treating amyloid...

Details Methods for using glucose pentasulfate for treating amyloid... Methods for using glucose pentasulfate for treating amyloid...

2008-05-13

2008-05-13

Jiang, Shaojia Anna (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S004100

Reexamination Certificate

active

07371731

ABSTRACT:
A pharmaceutical agent for treating an amyloid disease in a patient, wherein the pharmaceutical agent comprises glucose pentasulfate or a pharmaceutically acceptable salt thereof. The agent is directed to amyloid diseases in general and to type II diabetes in particular. Methods of treating an amyloid disease in a patient by administering therapeutically effective amounts of glucose pentasulfate are also presented.

REFERENCES:
patent: 5242932 (1993-09-01), Gandy et al.
patent: 5388574 (1995-02-01), Ingebrethsen
patent: 5643562 (1997-07-01), Kisilevsky et al.
patent: 5723589 (1998-03-01), Miljkovic et al.
patent: 6037327 (2000-03-01), Castillo et al.
patent: 6767898 (2004-07-01), Castillo et al.
patent: WO 95/06477 (1994-08-01), None
Snow et al. “Proteoglycans in the Pathogenesis of Alzheimer's Disease and Other Amyloidoses,” Neurobiology of Aging, vol. 10, pp. 481-497, 1989.
Puchtler et al. “On the Binding of Congo Red by Amyloid,” pp. 355-364, 1875 (publication information unknown).
Benson et al. “Serum Amyloid a Protein in Amyloidoses, Rheumatic, and Neoplastic Diseases,” Arthritis and Rheumatism, vol. 22, No. 1, pp. 36-42, Jan. 1979.
Kamei et al. “Amyloidoses Associated with Juvenile Rheumatoid Arthritis,” Acta Pathol. Jpn., vol. 32, No. 1, pp. 123-133, 1982.
McAdam et al. “Association of Amyloidosis with Erythema Nodosum Leprosum Reactions and Recurrent Neutrophil Leucocytosis in Leprosy,” Lancet, pp. 572-576, Sep. 27, 1975.
Metaxas et al. “Familial Mediterranean Fever and Amyloidosis,” Kidney International, vol. 20, pp. 676-685, 1981.
Harada et al. “Human Amyloid Protein: Chemical Variability and Homogeneity,” Journal of Histochemistry and Cytochemistry, vol. 19, No. 1, pp. 1-15, 1971.
Johnson et al. “Islet Amyloid, Islet-Amyloid Polypeptide, and Diabetes Mellitus,” New England Journal of Medicine, vol. 321, No. 8, pp. 513-518, Aug. 24, 1989.
Johnson et al. “Islet Amyloid Polypeptide: Mechanisms of Amyloidogenesis in the Pancreatic Islets and Potential Roles in Diabetes Mellitus,” Laboratory Investigation, vol. 66, No. 5, pp. 522-535, 1992.
Gejyo et al. “A New Form of Amyloid Protein Associated with Chronic Hemodialysis was Identified as β2-Microglobulin,” Biochemical and Biophysical Research Communications, vol. 129, vol. 3, pp. 701-706, Jun. 28, 1985.
Gejyo et al. “β2-Microglobulin: A New Form of Amyloid Protein Associated with Chronic Hemodialysis,” Kidney International, vol. 30, pp. 385-390, 1986.
Skinner et al. “The Prealbumin Nature of the Amyloid Protein in Familial Amyloid Polyneuropathy (FAP)-Swedish Variety,” Biochemical and Biophysical Research Communications, vol. 99, No. 4, 1316-1332, Apr. 30, 1981.
Saraiva et al. “Amyloid Fibril Protein in Familial Amyloidotic Polyneuropathy, Portuguese Type,” J. Clinical Invest., vol. 74, pp. 104-119, Jul. 1984.
Saraiva et al. “Studies on Plasma Transthyretin (Prealbumin) in Familial Amyloidotic Polyneuropathy, Portuguese Type,” J. Lab. Clin. Med., vol. 102, No. 4, pp. 590-603, Oct. 1983.
Tawara et al. “Amyloid Fibril Protein in Type I Familial Amyloidotic Polyneuropathy in Japanese,” J. Lab. Clin Med., vol. 98, No. 6, pp. 811-822, Dec. 1981.S.
Barner et al., “Donepezil Use in Alzheimer Disease,” Annals of Pharmacotheraphy, vol. 32, pp. 70-77, Jan. 1998.
Glenner et al. “Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein,” Biochemical and Biophysical Research Communications, vol. 120, No. 2, pp. 885-890, May 16, 1984.
Masters et al. “Amyloid Plaque Core Protein in Alzheimer Disease and Down Syndrome,” Proc. Natl. Acad. Sci. USA, vol. 82, pp. 4245-4249, Jun. 1985.
WHO-IUIS Nomenclature Sub-Committee, “Nomenclature of Amyloid and Amyloidosis,” Bulletin of the World Health Organization, vol. 71, No. 1, pp. 105-108, 1993
Ponte et al. “A New A4 Amyloid mRNA Contains a Domain Homologous to Serine Proteinase Inhibitors,” Nature, vol. 331, pp. 525-527, Feb. 11, 1988.
Tanzi et al. “Protease Inhibitor Domain Encoded by an Amyloid Protein Precursor mRNA Associated with Alzheimer's Disease,” Nature, vol. 331, pp. 528-532, Feb. 11, 1988.
Grundke-Iqbal et al. “Abnormal Phosphorylation of the Microtubule-Associated Protein τ (tau) in Alzheimer Cytoskeletal Pathology,” Proc. Natl. Acad. Sci USA, vol. 83, pp. 4913-4917, Jul. 1986.
Kosik et al. “Microtubule-Associated Protein Tau (τ) is a Major Antigenic Component of Paired Helical Filaments in Alzheimer Disease,” Proc. Natl. Acad. Sci. USA, vol. 83, pp. 4044-4048, Jun. 1986.
Lee et al. “A68: A Major Subunit of Paired Helical Filaments and Derivatized Forms of Normal Tau,” Science, vol. 251, pp. 675-678, Feb. 8, 1991.
Mandybur “Cerebral Amyloid Angiopathy: The Vascular Pathology and Complications,” Journal of Neuropathology and Experimental Neurology, vol. 45, No. 1, pp. 79-90, Jan. 1986.
Pike et al. “Structure-Activity Analysis of β-Amyloid Peptides: Contribution of the β25-35 Region to Aggregation and Neurotoxicity,” Journal of Neurochem., vol. 64, No. 1, pp. 253-265, 1995.
Pike et al. “In Vitro Aging of β-Amyloid Protein Causes Peptide Aggregation and Neurotoxicity,” Brain Research, vol. 563, pp. 311-314, 1991.
Pardridge et al. “Amyloid Angiopathy of Alzheimer's Disease: Amino Acid Composition and Partial Sequence of a 4,200-Dalton Peptide Isolated from Cortical Microvessels,” Journal of Neurochem., vol. 49, No. 5, pp. 1394-1401, 1987.
Harrigan et al. “Beta Amyloid is Neurotoxic in Hippocampal Slice Cultures,” Neurobiology of Aging, vol. 16, No. 5, pp. 779-789, 1995.
Flood et al. “Amnestic effects in mice of four synthetic peptides homologous to amyloid β protein from patients with Alzheimer disease,” Proc. Natl. Acad. Sci. USA, vol. 88, pp. 3363-3366, Apr. 1991.
Games et al. “Alzheimer-type neuropthology in transgenic mice overexpressing V717F β-amyloid precursor protein,” Nature, vol. 373, Feb. 9, 1995.
Flood et al. “An Amyloid β-protein fragment, Aβ[12-28], equipotently impairs post-training memory processing when injected into different limbic system structures,” Brain Research, vol. 663, pp. 271-276, 1994.
Murrell et al. “A Mutation in the Amyloid Precursor Protein Associated with Hereditary Alzheimer's Disease,” Science, vol. 254, Oct. 4, 1991.
Broeckhoven et al. “Amyloid β Protein Precursor Gene and Hereditary Cerebral Hemorrhage with Amyloidosis (Dutch),” Science, vol. 24, Jun. 1, 1990.
Haass et al. “The Swedish mutation causes early-onset Alzheimer's disease by β-secretase cleavage within the secretory pathway,” Nature Medicine, vol. 1, No. 12, Dec. 1995.
Hardy. “Framing β-amyloid,” Nature, vol. 1, Jul. 1992.
Levine. “Thioflavine T interaction with amyloid β-sheet struvtures,” Int. J. Exp. Clin Invest., vol. 2, pp. 1-6, 1995.
Naiki. “Kinetic Analysis of Amyloid Fibril Polymerization In vitro ,” Laboratory Investigation, vol. 65, No. 1, p. 104, 1991.
Levine. “Thioflavine T interaction with synthetic Alzheimer's desease β-amyloid peptides: Detection of amyloid aggregation in solution,” Protein Science, vol. 2, pp. 404-410, 1993.
Naiki. “First-Order Kinetic Model of Alzheimer's β-amyloid Fibril Extension In Vitro,” Laboratory Investigation, vol. 74, No. 2, p. 374, 1996.
Bloemen et al. “Adhesion molecules: a mew target for immunoliposome-mediated drug delivery,” FEBS Letters, vol. 357, pp. 140-144, 1995. [Not Available].
Ranade. “Drug Delivery Systems. 1. Site-Specific Drug Delivery Using Liposomes as Carriers,” Journal of Clinical Pharmac

Affiliated with

Also associated with

Rating

Methods for using glucose pentasulfate for treating amyloid... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for using glucose pentasulfate for treating amyloid..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for using glucose pentasulfate for treating amyloid... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2780670